

United States Patent and Trademark Office

UNITED STATES PATENT AND TRADEMARK OFFICE ALEXANDRIA, VA 22313-1450

Laura A. Donnelly One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003

In re Application of

MASURE, et al.

U.S. Application No.: 10/019,337

PCT No.: PCT/EP00/04918

Int. Filing Date: 26 March 2000

Priority Date: 29 June 1999

Attorney Docket No.: JAB-1512

NEUROTROPHIC FACTOR RECEPTOR For:

DECISION ON RENEWED

PETITION UNDER

37 CFR 1.137(b)

The renewed petition to revive under 37 CFR 1.137(b) filed 27 June 2003 in the above-captioned application is hereby **GRANTED** as follows:

On 08 May 2003, applicant was mailed a decision dismissing applicant's petition under 37 CFR 1.137(b). As detailed in the decision, a petition under 37 CFR 1.137(b) requesting that the application be revived on the grounds of unintentional abandonment must be accompanied by (1) the required reply, (2) the petition fee required by law, (3) a statement that the, "entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to this paragraph was unintentional" and (4) any terminal disclaimer and fee pursuant to 37 CFR 1.137(c) (where required). Applicant previously satisfied items (2) - (4) above.

A review of the application file reveals that applicant has currently satisfied item (1) in providing a Sequence Listing for the present application. As such, the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

This application is being returned to the United States Designated/Elected Office for processing in accordance with this decision. The 35 U.S.C. 371(c) date is 19 December 2001.

Derek A. Putonen

Attorney Advisor

Office of PCT Legal Administration

AGHA

Tel: (703) 305-0130 Fax: (703) 308-6459